Agilent Technologies Inc (NYSE:A) – Analysts at Jefferies Group lifted their Q3 2018 EPS estimates for Agilent Technologies in a research report issued on Thursday. Jefferies Group analyst B. Couillard now anticipates that the medical research company will post earnings of $0.64 per share for the quarter, up from their prior estimate of $0.63.
Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $0.66 EPS for the quarter, beating the Zacks’ consensus estimate of $0.58 by $0.08. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.16 billion. Agilent Technologies had a net margin of 4.25% and a return on equity of 17.70%. During the same quarter last year, the firm earned $0.53 earnings per share.
Shares of Agilent Technologies (A) opened at $71.97 on Monday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.23 and a quick ratio of 2.85. The company has a market cap of $23,250.00, a PE ratio of 32.13, a P/E/G ratio of 2.10 and a beta of 1.28. Agilent Technologies has a 12-month low of $50.58 and a 12-month high of $75.00.
In other news, insider Patrick Kaltenbach sold 7,358 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $69.28, for a total transaction of $509,762.24. Following the completion of the sale, the insider now directly owns 72,862 shares in the company, valued at approximately $5,047,879.36. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael R. Mcmullen sold 43,703 shares of Agilent Technologies stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $70.00, for a total transaction of $3,059,210.00. Following the sale, the chief executive officer now owns 302,837 shares of the company’s stock, valued at $21,198,590. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 175,029 shares of company stock valued at $12,349,106.
Institutional investors have recently modified their holdings of the stock. Dupont Capital Management Corp acquired a new position in shares of Agilent Technologies during the 3rd quarter worth approximately $101,000. Front Row Advisors LLC acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $106,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $126,000. AMG National Trust Bank acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $201,000. Finally, Premia Global Advisors LLC acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $204,000.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.